Pipeline

Preclinical
Phase 1
Phase 2
Phase 3
XF-73 Nasal

Prevention of post-surgical staphylococcal infection (US QIDP and Fast Track status)

Read More
XF-73 Dermal

Treatment of skin infections of antibiotic resistant bacteria associated with open wounds / broken skins

Project 1 – Treatment of skin infections of antibiotic resistant bacteria associated with open wounds / broken skin

Project 2 – Treatment of superficial skin infections of antibiotic resistant bacteria

Read More
XF-73 Drugs Research

Treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. Respiratory/dermal/oral mucositis

Read More
NTCD-M3

Prevention of C. difficile infection (CDI) recurrence

Read More
SPOR-COV™

Innate immune modulation for prevention of COVID-19 and influenza

Read More

XF-73 Nasal

…and is a novel compound being developed for the prevention of post-surgical Staphylococcal infections. XF-73 reported very positive clinical data in 2021.
Learn More

XF-73 Dermal

...and has been supported by the US government’s National Institute for Allergy and Infectious Diseases, (part of the US National Institutes of Health).
Learn More

XF-73 Drugs Research

...(including antibiotic resistant strains) leaving the bacteria unable to mount a resistance.
Learn More

NTCD-M3

...which is the non-toxigenic Clostridioides difficile strain M3 – for the prevention of recurring C. difficile gut infections (CDI).
Learn More

SPOR-COV™

...on a novel SPOR-COV innate immune system boosting treatment for the prevention of COVID-19.
Learn More